Roger Beadle
University of Aberdeen
12 Papers
44 Citations
Roger Beadle is an academic researcher from University of Aberdeen. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Improvement in Cardiac Energetics by Perhexiline in Heart Failure Due to Dilated Cardiomyopathy
Roger Beadle,Lynne Williams,Michael Kuehl,Sarah Bowater,Khalid Abozguia,Francisco Leyva,Zaheer Yousef,Anton J. M. Wagenmakers,Frank Thies,John D. Horowitz,Michael P. Frenneaux +10 more
TL;DR: Perhexiline improves cardiac energetics and symptom status with no evidence of altered cardiac substrate utilization and New York Heart Association functional class compared with placebo.
Magnetic resonance spectroscopy in myocardial disease.
TL;DR: 31-phosphorous magnetic resonance spectroscopy is a technique that allows the noninvasive characterization of the biochemical and metabolic state of the myocardium in vivo and is likely to play a role in the future of multimodalnoninvasive cardiac assessment.
25
Cardiac metabolism in hypertrophy and heart failure: implications for therapy.
TL;DR: In left ventricular hypertrophy and heart failure, these processes become disturbed, leading as will be discussed to impaired cardiac energetic status and to further impairment of cardiac function.
25
Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome
Satnam Singh,Roger Beadle,Donnie Cameron,Amelia Rudd,Maggie Bruce,Baljit Jagpal,Konstantin Schwarz,Gemma Brindley,Fergus Mckiddie,Chim C. Lang,Dana Dawson,Michael P. Frenneaux +11 more
TL;DR: It is hypothesized that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with HFpEF.
10
Device therapy in hypertrophic cardiomyopathy
Roger Beadle,Lynne Williams +1 more
TL;DR: Although implantable cardioverter–defibrillators have proven to be effective in the prevention of sudden cardiac death, careful consideration of device implantation in high-risk patients is necessary in view of the potential for device complications and their impact on quality of life.
4